Background: Despite modeling-based epidemiological studies of MASLD, precise estimates of the prevalence and health-care resource utilization in outpatient clinical practice are unknown. We assessed, in a real-life setting, the prevalence of suspected/confirmed MASLD and described health-care resource utilization. Methods: A prospective, observational study of patients attending the outpatient hepato-gastroenterology clinics of eight European tertiary care centers during three months. Follow-up data of patients with suspected/confirmed MASLD were recorded 12 months after the screening visit: final diagnosis, disease stage, diagnostic work-up and the use of health-care resources. Findings: 5240 outpatients from Germany, France, United Kingdom, Switzerland, Italy, Spain and Slovakia were screened. The main reasons for visit were: chronic viral hepatitis, 33.4% (1749/5240), miscellaneous hepatobiliary conditions including neoplasms, 32.9% (1725/5240) and known/suspected MASLD, 24.7% (1293/5240) (pooled prevalence of 26.1% (95% CI: 19.1–34.7)). 1134 suspected/confirmed MASLD patients were included, the diagnosis was confirmed in 80.2% (909/1134). Significant fibrosis was documented in 22.7% (257/1134) and cirrhosis (including burn-out MASLD) in 21.3% (241/1134). Procedures performed differed between countries, overall 66.4% (753/1134) had imaging studies, 65.3% (740/1134) non-invasive fibrosis tests, 20.4% (231/1134) liver biopsy, while referral for further cardiometabolic assessment or therapy was minimal (144/1134, 15.8%). The cost of all procedures and visits was in the range of that recommended for exploring hepatitis C before treatment, although highly variable between countries. Interpretation: MASLD was the second most frequent single cause for outpatient visits in eight European tertiary care centers. Significant fibrosis including cirrhosis was diagnosed in 44% of patients. The cost of required additional visits and procedures was equivalent to that recommended for hepatitis C before antiviral treatment. Funding: IMI2-Grant Agreement 777377-LITMUS.

Health-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study / Ratziu, V., Dufour, J., Ponnaiah, M., Pais, R., Thormann, M., Bugianesi, E., Marra, F., Boyle, M., Hallsworth, K., Aspite, S., Drazilova, S., Ravaioli, F., Gomez, M.R., Kara, L., Anstee, Q.M., Schattenberg, J.. - In: THE LANCET REGIONAL HEALTH. EUROPE. - ISSN 2666-7762. - ELETTRONICO. - 71:(2026), pp. 101893.0-101893.0. [10.1016/j.lanepe.2026.101893]

Health-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study

Marra, Fabio;Aspite, Silvia;
2026

Abstract

Background: Despite modeling-based epidemiological studies of MASLD, precise estimates of the prevalence and health-care resource utilization in outpatient clinical practice are unknown. We assessed, in a real-life setting, the prevalence of suspected/confirmed MASLD and described health-care resource utilization. Methods: A prospective, observational study of patients attending the outpatient hepato-gastroenterology clinics of eight European tertiary care centers during three months. Follow-up data of patients with suspected/confirmed MASLD were recorded 12 months after the screening visit: final diagnosis, disease stage, diagnostic work-up and the use of health-care resources. Findings: 5240 outpatients from Germany, France, United Kingdom, Switzerland, Italy, Spain and Slovakia were screened. The main reasons for visit were: chronic viral hepatitis, 33.4% (1749/5240), miscellaneous hepatobiliary conditions including neoplasms, 32.9% (1725/5240) and known/suspected MASLD, 24.7% (1293/5240) (pooled prevalence of 26.1% (95% CI: 19.1–34.7)). 1134 suspected/confirmed MASLD patients were included, the diagnosis was confirmed in 80.2% (909/1134). Significant fibrosis was documented in 22.7% (257/1134) and cirrhosis (including burn-out MASLD) in 21.3% (241/1134). Procedures performed differed between countries, overall 66.4% (753/1134) had imaging studies, 65.3% (740/1134) non-invasive fibrosis tests, 20.4% (231/1134) liver biopsy, while referral for further cardiometabolic assessment or therapy was minimal (144/1134, 15.8%). The cost of all procedures and visits was in the range of that recommended for exploring hepatitis C before treatment, although highly variable between countries. Interpretation: MASLD was the second most frequent single cause for outpatient visits in eight European tertiary care centers. Significant fibrosis including cirrhosis was diagnosed in 44% of patients. The cost of required additional visits and procedures was equivalent to that recommended for hepatitis C before antiviral treatment. Funding: IMI2-Grant Agreement 777377-LITMUS.
2026
71
0
0
Ratziu, Vlad; Dufour, Jean-François; Ponnaiah, Maharajah; Pais, Raluca; Thormann, Maximilian; Bugianesi, Elisabetta; Marra, Fabio; Boyle, Marie; Halls...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1501254
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact